Pharmaceuticals company Hester Biosciences announced Q2FY26 results Revenue from operations: Rs 709.69 million against Rs 836.92 million during Q2FY25, change -15%. EBITDA: Rs 235.97 million against Rs 219.55 million during Q2FY25, change 7%. EBITDA Margin: 33% for Q2FY26. PAT: Rs 143.31 million against Rs 83.91 million during Q2FY25, change 71%. PAT Margin: 20% for Q2FY26. EPS: Rs 16.85 for Q2FY26. Result PDF
Pharmaceuticals company Hester Biosciences announced Q1FY26 results Revenue from operations: Rs 841.05 million compared to Rs 822.67 million during Q1FY25, change 2%. EBITDA: Rs 261.79 million compared to Rs 197.35 million during Q1FY25, change 33%. EBITDA Margin: 31% for Q1FY26. PAT: Rs 172.96 million compared to Rs 74.86 million during Q1FY25, change 131%. EPS: Rs 20.33 for Q1FY26. Animal Healthcare Division: In Q1FY26, the division recorded a 33% decline in sales, primarily due to timing delays in key government Immunisation programmes for PPR and Lumpy Skin Disease, in which Hester’s PPR and Goat Pox vaccines respectively, are widely used, have got delayed. Poultry Healthcare Division: The Poultry Healthcare Division recorded a 2% growth in Q1FY26, led by robust demand for key vaccines, particularly for Newcastle Disease and Marek’s Disease. Result PDF
Conference Call with Hester Biosciences Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q4FY25 results Revenue from operations: Rs 819.25 million compared to Rs 792.55 million during Q4FY24, change 3%. Gross Profit Margin: Rs 611.83 million compared to Rs 577.16 million during Q4FY24, change 6%. EBITDA: Rs 135.41 million compared to Rs 205.48 million during Q4FY24, change -34%. EBITDA margin: 17% for Q4FY25. PAT: Rs 15.41 million compared to Rs 63.95 million during Q4FY24, change -76%. PAT margin: 2% for Q4FY25. Result PDF
Pharmaceuticals company Hester Biosciences announced Q3FY25 results Divisional Product Sales: Rs 632.18 million, down 6% YoY from Rs 669.83 million Revenue from Operations: Rs 632.18 million, down 6% YoY from Rs 669.83 million Hester Nepal: Rs 8.09 million, up 2% YoY from Rs 7.91 million Hester Africa: Rs 8.05 million, up 11% YoY from Rs 7.26 million Gross Profit Margin: Rs 435.93 million, down 6% YoY from Rs 463.44 million EBITDA: Rs 138.45 million, up 12% YoY from Rs 123.53 million EBITDA %: 22%, up 4% YoY from 18% PAT: Rs 114.08 million, up 184% YoY from Rs 40.20 million PAT %: 18%, up 12% YoY from 6% EPS: Rs 13.41, up 184% YoY from 4.73 Result PDF
Pharmaceuticals company Hester Biosciences announced Q2FY25 results Revenue from operations: Rs 836.92, compared to Q2FY24 Rs 704.55 change 19%. Consolidated EBITDA: Rs 219.55 million change 15% Q2FY25 Consolidated Divisional Product sales up by 21% & Profit up by 108%. Hester Nepal achieved net profit of Rs 0.29 million in Q2FY25, reversing from a loss of Rs 7.05 million in Q2FY24. The subsidiary fulfilled export orders from government tenders and met domestic vaccine demand, showcasing its growth potential. Hester Nepal remains debt-free with strong cash flows from the quarter. Hester Africa reduced its net loss to Rs 23.67 million in Q2FY25, down from net loss of Rs 49.17 million in Q2FY24. Hester Africa is actively participating in international tenders and meeting trade demands across various African countries, with increasing awareness and demand for vaccines. Result PDF
Conference Call with Hester Biosciences Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q1FY25 results: Q1FY25 Standalone Divisional Product sales up by 37% & Profit up by 30% Q1FY25 Consolidated Divisional Product sales up by 35% & Profit up by 9% The divisional performance has demonstrated growth in the current quarter compared to Q1FY24, with sales increasing by 37%. The overall sales show a decrease of 9% QoQ, primarily attributed to the one-time sales of other pharmaceutical products in Q1FY24. Hester focused on higher-margin products and solutions in Q1FY25, leading to a significant rise in gross profit margin from 57% to 69%. Increased revenue from divisional product sales allowed for better absorption of fixed costs, resulting in a 5% improvement in EBITDA%. Overall absolute PAT increased by 30% and PAT% ratio increased by 3%, reflecting improved operational efficiency. Result PDF
Conference Call with Hester Biosciences Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.